Clinical Trial Update: A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating meloxicam plus filgrastim in patients with multiple myeloma and non-Hodgkin's lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Filgrastim (filgrastim)
• MELOXICAM (MELOXICAM)

Snippet

Sponsor: Sherif S. Farag | Conditions: Multiple Myeloma, Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-02-21